{"name":"Ocular Therapeutix, Inc.","slug":"ocular-therapeutix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"OTX-TKI","genericName":"OTX-TKI","slug":"otx-tki","indication":"Dry eye disease","status":"phase_3"},{"name":"Ophthalmic Insert","genericName":"Ophthalmic Insert","slug":"ophthalmic-insert","indication":"Dry eye disease","status":"phase_3"},{"name":"Punctum Plug","genericName":"Punctum Plug","slug":"punctum-plug","indication":"Treatment of dry eye disease","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OTX-TKI (axitinib implant)","genericName":"OTX-TKI (axitinib implant)","slug":"otx-tki-axitinib-implant","indication":"Metastatic renal cell carcinoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dexamethasone, 0.4mg","genericName":"Dexamethasone, 0.4mg","slug":"dexamethasone-0-4mg","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Dextenza Ophthalmic Insert","genericName":"Dextenza Ophthalmic Insert","slug":"dextenza-ophthalmic-insert","indication":"Post-operative inflammation and pain following ocular surgery","status":"phase_3"}]}],"pipeline":[{"name":"OTX-TKI","genericName":"OTX-TKI","slug":"otx-tki","phase":"phase_3","mechanism":"OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"OTX-TKI (axitinib implant)","genericName":"OTX-TKI (axitinib implant)","slug":"otx-tki-axitinib-implant","phase":"phase_3","mechanism":"OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.","indications":["Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Ophthalmic Insert","genericName":"Ophthalmic Insert","slug":"ophthalmic-insert","phase":"phase_3","mechanism":"An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation.","indications":["Dry eye disease","Ocular surface disease"],"catalyst":""},{"name":"Dexamethasone, 0.4mg","genericName":"Dexamethasone, 0.4mg","slug":"dexamethasone-0-4mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dextenza Ophthalmic Insert","genericName":"Dextenza Ophthalmic Insert","slug":"dextenza-ophthalmic-insert","phase":"phase_3","mechanism":"Dextenza is a corticosteroid-eluting ophthalmic insert that delivers dexamethasone directly to ocular tissues to reduce inflammation and pain following eye surgery.","indications":["Post-operative inflammation and pain following ocular surgery","Corneal refractive surgery pain and inflammation"],"catalyst":""},{"name":"Punctum Plug","genericName":"Punctum Plug","slug":"punctum-plug","phase":"phase_3","mechanism":"Punctum Plug is a biodegradable collagen shield used to treat punctal occlusion.","indications":["Treatment of dry eye disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHNDR2RoWGUwU3lJeHRocVBKaW5WQ09zM2xwWEQzS1JTMndGcFhUcDV0OUpsNTBycEgwVUY3YUJjZ01EOEJJOXdzaER6RF9yQncwc2txQmlGUnktdXBzNXFWVFhpREthbmlabF9vd0JCYTdyYkJnTUxaNkFsbl9tOGt0Qko4TWRmbjh0QnhQa1AtVkRESktTR2lR?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market - openPR.com","headline":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBwU0RnLUl0MjVqU0xQN0hQbDA3d2NEWmZndDlRSXREVGVGVmR0Mk1yTEplQjlUelVOdS1HejdJYjBNang5SWhyM3pqVFJPOVdWNlNFVGtmQmQ4RGo4VjRZ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill","headline":"OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNeFVfZ1F2LWFobnBLNENTMHJUZ2tTUkMtT2JTSXNlOG04NHdlbDN0c2dWcldFaWYzakxuNjRnc0Q1TWJ1VndOSWVhblpUazd1bGhXbGhxUWhRNi1HZVpHalBJbVc0QVRhMXVjSlMtdHJHUEdmME1OcTktb0tDUEY5OXVWZU1sQ1NxYURrUWdEYzZucjVDNmJjZXZhOGRjMUxVMEc4RHFsMGF1SEl4NVMwdTk3NEt1SW1kWkpEb2UwbHRWbVpNbHRiNmhnWlBXVkJxeWR1SWZ4a0k1UlZ5dmpSWllSU29tSU92NXc?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight - Barchart.com","headline":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPa1ZvVGVNQWtBV1FmLU5vWVAzTF9wZnVzZW5qcDFLQzNvN29WMDZFT0pQd29WRENZby1TZUFPZndRb1Q2Q1VvLV9LanpuZkgtVEZqVk10dndkTVRXS2JKTnpFRUF1cW5sSHdyOW1jUWtfbE81QnNUR0l2N1AxeENmRm5DczU0U0tRblZWSks4Y3dGeE5YWUpaa1M2R1o0cUtScXZDS28tbHBuOElLSFpQcEJMN0RBMm9j?oc=5","date":"2026-03-23","type":"pipeline","source":"Fierce Pharma","summary":"EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - Fierce Pharma","headline":"EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQdDAzdjlTUGNlZlhYTTd3ZHdfWmNLZWRuQnlBMzhwUEZFajlIVTVzaHRacTY2Zi1RZndrRFYyOC13ZUl6MmVpR1UzdG52ZHNQT2tjZ1VzWnVkMVdZa3VCNEJ5dzBSdXI3eGIzcXRpSHZPNzRvWWo2WXE5SW5uWTVCTUFNckpUQnIwZGY5V0xjZGVlc0wtQ0pGN3dJTG80S0dUUXBYU1EyOXd1YlB3SjA0ZlFWMVd0TUdSazFoclVfRXZ2UGp3Vmw0?oc=5","date":"2026-03-22","type":"pipeline","source":"Reuters","summary":"EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters","headline":"EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONS1IbXZkM1lXWko0SHdCVFdDem83ci14eHdUX2xVRXVLOThEQmZLTHJ5aFRUTk5jUmdHdjQ5UUhUSzdlY1JPei1KdEtXMHlkU0NCVVVLQ25XNVFXdXNYZmx1eEwwNG1uUmExc2VVeGdMT0tzR2RZejhYQ1luZGZnQTNONVJZUVJVRUZKSFN2ZzdVSU0?oc=5","date":"2026-03-12","type":"earnings","source":"Yahoo Finance","summary":"Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance","headline":"Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcjNicllkY3hSaEdmc05nN0Rqa2tHZFV5X3VJX3d4bENNeWhHVFJNOG5heFFlMFBESDJsRHRTazJudlVkeUpORVQyYVhjRGhIWFlzUjFobUY0SmFHU2l2Skd5RzF5aGNQOXFjTUNENTN5YVJuMlZqVDhFTFkxbGlPMUNtYWRkbEE?oc=5","date":"2026-02-05","type":"trial","source":"statnews.com","summary":"A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment - statnews.com","headline":"A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQR3FQc3doTmRKelhIQ25rbE5GSVFGM25ncU15V2VBb1Z3TkJWVXVTcG91eTBUWXZaZm5pdDQxY1RUZi1DdkF2ME5Ld1A1ZWVZbzh4eDhYeEx2WDdFbXVIMDlHdVd6N01qWUlQeklzcDF2T0ppTnYwTGYtcFNkOVF4c1dSMWIxdVZnaFh6UXMwdXFpOUFMMkVIMTZHamJXdw?oc=5","date":"2026-01-22","type":"pipeline","source":"The Pharma Letter","summary":"Ocular Therapeutix names David Robinson as global CCO - The Pharma Letter","headline":"Ocular Therapeutix names David Robinson as global CCO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOUzZsNXoxS2F2TzVNWWpwN0NpZlAzcmo3a3RveS1FQmN5V2pXbFM4RHpTM0hWZ1cwcERjY29aTjJvcTQ1Ni1sREhCeTRWa1JfaXFtU2szcnp4TGhERmk0ZFNNUnVsdFI1X2tyLUpfaVJ2ZmliaVN6TkpvTGRKU2hhUjdEYjFNRUtlNHJJaGFZNXFqbUpNZ2JqWGtaQ096RGRDQ0RFYlh6US0yNVlDNWM3dkxMcWZSVk5UWmlMc3p1QThHd1p2V2dRX3MweGtXeEVzMFY3TEg1dGJNMlM0MmRLU3A4MWhGdw?oc=5","date":"2026-01-21","type":"pipeline","source":"GlobeNewswire","summary":"Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - GlobeNewswire","headline":"Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNZWRrT3lNclFNRkhFdkoyVGZQNFFfWEhBQmQtclpVZnhMbDVzMWdpVGFaZ1ctMHpodFktUjNuUkNFZ01JMmo0akdWVTlEYXRyVHVKUnJsbGExZDd0d2Q2YkRHLV9pQnpoMV9jSU5KNTZvSkpGMWRWZ2w4Uzh5YmhCeg?oc=5","date":"2026-01-16","type":"pipeline","source":"pharmaphorum","summary":"Sanofi linked to takeover bid for Ocular Therapeutix - pharmaphorum","headline":"Sanofi linked to takeover bid for Ocular Therapeutix","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYlJMdEVrS1NpOV9aa3NDUnU5RVRzampwWkpLbmpmSjYzV0xfT2JKVE1jMzA4dHU2SVNfeWd3MmQyT3lQeE1DT0tKcmRhdWt0aHQ3Q1FJYW1wdFdLZWxNRnBjN1c2dXJvUDcxUDYxSVVDNXl0Y000cGZyRzlLUkg0QlpjUzNCNFJFbWhV?oc=5","date":"2026-01-15","type":"pipeline","source":"Investor's Business Daily","summary":"Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Investor's Business Daily","headline":"Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPQk1GUHRsc095V1pWWWNIaVQ1RHJ5d192N3YtdDhXcDRpVW9DWGRTcDFIanlueFBia3lUWUhfN09YMUFKeWxkbV9KdjBjSTA3LVpLU0FmWU9sd2xWT0dEd04tb3JFcFpQalRia1YtMjdJcFhpTkFBWGZ6enVzM1pEVUVhQW5zWUs2WDVMUTdfenRGTzJPTl9UbzlPME1KVGlUZVhGLQ?oc=5","date":"2026-01-15","type":"pipeline","source":"seekingalpha.com","summary":"Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix (NASDAQ:SNY) - seekingalpha.com","headline":"Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix (NASDAQ:SNY)","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}